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Mesenchymal stem cells (MSCs) represent a promising cell population for cell therapy and regenerative medicine applications.
However, how variations in glucose are perceived by MSC pool is still unclear. Since, glucose metabolism is cell type and tissue
dependent, this must be considered whenMSCs are derived from alternative sources such as the heart.The zinc finger transcription
factor Egr-1 is an important early response gene, likely to play a key role in the glucose-induced response. Our aimwas to investigate
how short-term changes in in vitro glucose concentrations affect multipotent cardiac tissue-derived MSCs (cMSCs) in a mouse
model of Egr-1 KO (Egr-1−/−). Results showed that loss of Egr-1 does not significantly influence cMSC proliferation. In contrast,
responses to glucose variations were observed in wt but not in Egr-1−/− cMSCs by clonogenic assay. Phenotype analysis by RT-PCR
showed that cMSCs Egr-1−/− lost the ability to regulate the glucose transporters GLUT-1 and GLUT-4 and, as expected, the Egr-1
target genes VEGF, TGF𝛽-1, and p300. Acetylated protein levels of H3 histonewere impaired in Egr-1−/− compared towt cMSCs.We
propose that Egr-1 acts as immediate glucose biological sensor in cMSCs after a short period of stimuli, likely inducing epigenetic
modifications.
1. Introduction
Mesenchymal stem cells (MSCs) are widely distributed in
the body and are an important source of tissue formation
and regeneration. Cardiac tissue-derived MSCs (cMSCs)
are resident in the heart, within the cardiac stromal cell
compartment, a key component of the stem cell niche [1, 2].
Glucose is the main fuel source for MSCs, whose pool
and metabolism are influenced in both physiological and
pathological conditions [3, 4].
The way in which glucose variations in MSCs exert their
effects on stem cell pool is a highly interesting issue. Elevated
concentrations of glucose have been demonstrated to impair
original important cellular functions, such as apoptosis, cell
viability, and proliferation as well as colony forming ability
both in vitro and in vivo of MSCs regardless of their tissue
of origin [3, 5, 6]. In contrast, glucose reduction improves all
the aforementioned properties, due to the overall beneficial
effects of caloric restriction reported in MSCs such as a
decrease in cell death, senescence, and aging [7].
Glucose depletion seems also able to augment the in
vivo ability of MSCs to repair infarct myocardium [7]. In
addition, in rat multipotent adult progenitor cells but not
in human MSCs hyperglycemia has been correlated to the
suppression of specific growth factors [8, 9], thus highlighting
the fact that differences in the effect of glucose on MSCs
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might exist between species. Moreover, hyperglycemia has
been demonstrated to alter gene expression and even to
drive the mesodermal transdifferentiation of MSCs towards
a preferential adipogenic pathway at the expense of the
chondrogenic and osteogenic lineages [6, 10]. In other cell
systems such as endothelial cells, transient hyperglycemia
has been reported to cause relevant transcriptional changes,
thus offering an explanation for the persistent presence
of systemic complications in diabetic patients returning to
normal glycemic levels [11].
Taken together these observations have suggested that
damage caused by a dysregulation in the glucose level
tolerance may affect stem cell properties in a long term and
irreversible fashion.
The zinc finger transcription factor Egr-1 is a member of
a group of early response genes [12, 13]. A variety of stimuli,
ranging from hormones to UV light, are able to activate Egr-
1, affecting several cellular processes such as proliferation,
differentiation, apoptosis, and growth [14–17]. Egr-1 is also
responsive to glucose [18]. Glucose induces early growth
response gene (Egr-1) expression in pancreatic beta cells, [19],
a stress signaling for all cells. The involvement of Egr-1 in
insulin production of 𝛽-pancreatic cells [12], thus mediating
the insulin resistance process inmice, has been reported [20].
Recently, human bone marrow-derived MSCs genetically
modified to express insulin using the glucose-responsive
Egr-1 promoter have been tested for diabetes therapy [21].
Egr-1 is highly expressed inMSCs, representing a conver-
gence point of multiple signaling pathways, mainly involved
in the production of growth factors critical to their regenera-
tive properties [22].
To the best of our knowledge, nothing has been reported
so far concerning the role of Egr-1 in response to glucose
stress in cMSCs. Thus, the question of whether Egr-1 has
any role in the biological response to glucose in cMSCs
still remains unexplored. In the present report, we have
investigated the in vitro short-term effects of the response of
Egr-1 to glucose in cMSCs.
2. Materials and Methods
2.1. Animal Model and Surgery. The study was conducted
using C57BL/6 wild-type (wt) and Egr-1 deficient mice
(Egr-1−/−) obtained as previously reported [13]. Mice were
handled and sacrificed in compliance with the European
Convention on Animal Care. They have also received human
care in accordance with the principles of Laboratory Animal
Care and the Guide for the Care and Use of Laboratory
Animals (ILAR 1996). The study protocol was approved by
the Local Ethical Committee.
2.2. Cardiac Tissue-Derived Mesenchymal Stem Cell (cMSCs)
Isolation and Culture. Cardiac tissue-derived mesenchymal
stem cells (cMSCs) were isolated from hearts of 2-month-
old wt and Egr-1−/− homozygous mice. Hearts were excised
and kept in a sterile Falcon tube with complete biopsy
medium (Iscove’s modified Dulbecco’s medium (IMDM)
supplemented with 20% fetal bovine serum (FBS), 100U/mL
penicillin, and 100 𝜇g/mL streptomycin) and transported to
the laboratory at 4∘C and processed within 4 h.
Specimens were then washed with PBS supplemented
with 5% amphotericin-B and 5% penicillin-streptomycin
and minced using a sterile scalpel in a 100mm petri dish
into small pieces, and the fragments were transferred into
a clean tube filled with the enzymatic digestion solution
containing 1 : 1 Ham’s-F12, 0.05% Trypsin, 0.02% EDTA,
and 3mg/mL collagenase type-I. Samples were incubated
at 37∘C in a shaking water bath for 2-3 hours [23]. The
enzymatic digestion was blocked with PBS/20%FBS and the
digested solution was filtered with a 70 𝜇m cell strainer. Cell
suspension was centrifuged at 456×g for 10min at room
temperature. Cellular pellet was transferred in a sterile tube
and resuspended in complete biopsy medium and seeded in
a T25 ventilated flask and incubated at 37∘C with 5% CO
2
.
After 24 h, half of the medium was removed and replaced
with fresh complete medium. When cells reached the 70–
80% confluence, they were detached by 0.05% Trypsin and
0.02% EDTA, centrifuged at 377×g for 5min, and counted
by Trypan Blue. Cells were seeded in complete growth
medium (IMDM supplemented with 10% FBS, 1% penicillin-
streptomycin, 1% L-glutamine, 1% nonessential amino acids,
and 1% amphotericin-B) at a density of 6.000 cells/cm2. Half
of the medium was changed every 3 days. Experiments were
performed expanding cMSCs between passages 3–5.
2.3. FACSAnalysis. For FACS analysis, cMSCswere treated as
we previously described with little modifications [23]. Briefly,
cells were stained for 30min with the following conjugated
primary antibodies: PE anti-mouse CD-31 (clone 390, Cat.
number 102408 Biolegend), APC anti-mouse CD-45 (clone
30-F11, Cat. number 103112 Biolegend), and FITC anti-mouse
Ly-6A/E (Sca-1) (clone D7, Cat. number 108106 Biolegend).
Thereafter, cells were washed with cold PBS-FACS flow and
acquired using FACSAria II (B&D, San Jose, CA, USA). For
detection of apoptosis, cMSCs from wt and Egr-1−/− were
cultured in basal medium for 24 and 48 hours and then
collected and stained for 30 minutes with Annexin V-FITC
antibody (Becton and Dickinson Cat. number 556420) and
counterstained with propidium iodide (10 ng/mL, Sigma) in
order to exclude dead cells. Identical instrument settings
were used for all conditions. All cytofluorimetric data were
acquired by using DiVa Software (v6.1.1, B&D, San Jose, CA,
USA) and analyzed by Flowing Software (v2.5.1, TurkuCentre
for Biotechnology, Turku, Finland).
2.4. cMSC Conditioning with Glucose. cMSCs were detached
by 0.05% Trypsin/0.02% EDTA, counted by Trypan blue,
seeded in complete growth medium, and allowed to adhere
overnight. Thereafter, cells were starved with IMDM sup-
plemented with 0.2% FBS and after 12 h the medium was
changed and replaced with fresh Dulbecco’s modified Eagle
medium (DMEM) containing the following glucose concen-
trations: (I) no glucose (DMEMno glucose, Gibco Cat. num-
ber 11966-025); (II) 25mM (DMEM 25mM glucose, Sigma
Cat. number D5671); (III) 50mM (DMEM 25mM glucose
with a further supplement of glucose to reach 50mM).
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Table 1
Target Sequence
18S forward AAATCAGTTATGGTTCCTTTGGTC
18S reverse GCTCTAGAATTACCACAGTTATCCAA
Egr-1 forward CCTATGAGCACCTGACCACA
Egr-1 reverse TCGTTTGGCTGGGATAACTC
p300 forward ACATGATGCCTCGGATGACT
p300 reverse TAGGGGGCTGTGGCATATT
GLUT-1 forward CGCAACGAGGAGAACC
GLUT-1 reverse GCCGTGTTGACGATACC
GLUT-4 forward GACGGACACTCCATCTGTTG
GLUT-4 reverse GCCACGATGGAGACATAGC
TGF𝛽1 forward TGGAGCAACATGTGGAACTC
TGF𝛽1 reverse GTCAGCAGCCGGTTACCA
VEGF forward AAAAACGAAAGCGCAAGAAA
VEGF reverse TTTCTCCGCTCTGAACAAGG
2.5. Proliferation Assay. cMSC proliferation rate was evalu-
ated by Trypan Blue exclusion assay [24]. Briefly, cMSCs were
seeded in quintuplicate at density of 2500 cells/cm2 in 24-well
plate and subjected to different concentrations of glucose as
described above for 0, 48, and 168 h (7 days).
2.6. Colony Forming Unit Fibroblasts Assay (CFU-F). For
clonogenic assay, cMSCs were seeded at low density
(40 cells/cm2) in a 60mm petri dish and subjected to differ-
ent concentrations of glucose as described before. After 2
weeks of incubation, the petri dish was gently washed with
PBS, fixed with 4% paraformaldehyde, and incubated for
2min with absolute Giemsa (Sigma, St. Louis, MO, USA) and
then washed again in distilled water and incubated for 13min
with diluted Giemsa (1 : 20 distilled water, Sigma, St. Louis,
MO, USA) [23]. The petri was washed with distilled water
and cell clusters with a diameter ≥5mm were considered
colonies observed and counted by optical microscope.
2.7. Gene and Protein Expression Profiling. RNA was
extracted from preconditioned cMSCs. Briefly, cells were
plated at density of 6.000 cells/cm2 and treated as described
before. After 2 h, they were detached with a scraper and RNA
was extracted using RNeasy MicroKit (Quiagen, Hilden,
Germania) [24–27]. cDNA synthesis was performed from
1 𝜇g RNA by usingHigh Capacity cDNAReverse Transcription
Kit. Real-time PCR was carried out by using SensiMix SYBR
Hi-ROX kit (Bioline, London, UK). The relative ratio and
standard deviation between treated samples were calculated
using comparative 𝐶
𝑡
method (ΔΔ𝐶
𝑡
value). Transcript
levels were assessed by qPCR using Sensimix Sybr Green
in a MiniOpticon instrument equipped with CFX software
(Biorad) for 40 thermal cycles (95∘C for 15 seconds, 60∘C
for 10 seconds, and 72∘C for 30 seconds). The set of gene
analyzed and the primers sequence are listed in Table 1. 18S
was used as housekeeping gene and the expression levels of
cells in standard culture conditions (25mM glucose) as the
reference for normalization.
2.8. Western Blot. After glucose conditioning in culture,
cMSCs were washed. For nuclear extracts, cells were
trypsinized, rinsed with PBS, and collected by centrifugation.
Cells were then suspended in hypotonic buffer (10mM
HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, and 0.1mM
EGTA) and placed on ice for 15 min. NP40 was added to
a final concentration of 0.5%. Cells were spun top speed
for 30 s before the supernatant (cytoplasmic fraction) was
collected. The remaining pellet was washed with hypotonic
buffer, resuspended in ice-cold RIPA buffer (10mM Tris pH
8, 1% Triton, 0.1% SDS, 0.1% Deoxycholate, 140mM NaCl,
and 1mM EDTA) and a cocktail of protease inhibitors (1mM
DTT, 1mM PMSF, and 1 Protease inhibitor tablet/10mL
Sigma), placed on ice for 20min, and sonicated and spun at
15000×g for 15 min to remove debris and collect the super-
natant (nuclear fraction). Supernatants were boiled for 5min
in a Laemmli sample buffer. Equivalent protein quantities, as
determined by Bradford, were loaded on each gel. Proteins
were separated by 15% SDS-PAGE electrophoresis and elec-
trotransferred to polyvinylidene difluoride membranes and
incubated o/n at 4∘C with the primary antibodies against
rabbit acetyl histone H3 (1 : 1000, Upstate Cat. N. 06-599) and
mouse histone H3 (1 : 5000, Upstate Cat. number 05-499).
A horseradish peroxidase-conjugate secondary antibody is
incubated for 1 h at RT (Amersham mouse Cat. number
NA93IVS, rabbit NA934VS). The membranes were devel-
oped by enhanced chemiluminescence kit (ECL, Amersham).
Densitometric analysis has been performed with ImageJ
densitometry software.
2.9. Statistical Analysis. Statistical analysis was performed
and the data plotted using GraphPad Prism 5 software (San
Diego, USA). The independent sample two-tailed 𝑡-test with
associated 95% confidence intervals was used to compare
the single data. For multiple comparisons, the one analysis
of variance (ANOVA) test and the Bonferroni post hoc test
were used. 𝑃 values < 0.05 were considered to be significant.
Experiments were performed three times. Data are expressed
as means ± SEM unless specified.
3. Results
3.1. Proliferation Responses to Glucose Administrations.
cMSCs derived from wt and Egr-1−/− mice were firstly iso-
lated and phenotypically analyzed by cytofluorimetry accord-
ing to the expression of differentiation antigens on the surface
of murine cardiac stromal cells as previously reported [28].
As displayed in Figure 1(a), no difference in cell morphol-
ogy could be found between cMSCs derived from wt or Egr-
1−/− mice when observed under inverted-phase microscope.
In addition, after isolation only the percentage of the Sca-
1+/CD45−/CD31+ subset was statistically significant higher in
Egr-1−/− cMSCs compared to wt (𝑃 = 0.02, Figure 1(b)). A
similar phenotype with regard to the Sca-1+/CD45−/CD31−,
the Sca-1+/CD45+/CD31+, and the Sca-1+/CD45+/CD31−
subset was observed in wt and Egr-1−/− cMSC.
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Figure 1: (a) Optical images of cMSCs derived from wt and Egr-1−/− mice showing no difference in cell morphology. Magnification 10x.
(b) Immunophenotype of wt and Egr-1−/− cMSCs. FACS analysis histograms display that, among the four subsets, only the percentage of
Sca-1+/CD45−/CD31+ cells was higher in Egr-1−/− than in wt cMSCs. ∗𝑃 < 0.05. The error bars represent the SD.
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Figure 2: Cell proliferation of cMSCs subjected to glucose variations in culture and in presence of 0.2% FBS and measured by Trypan Blue
exclusion assay by counting viable cells. No significant difference in cell proliferation can be observed either at increased concentrations or
time exposure of glucose and between wt and Egr-1−/− cMSCs. The error bars represent the SD.
Afterwards, cMSCs were administered with different
concentrations of glucose in vitro. Cell proliferation was then
assessed by Trypan Blue exclusion assay at different time
intervals (0, 48 and 168 hours). Experiments were performed
in the presence of low serum (0.2% FBS), in order to avoid
possible interference of the serum on cell proliferation, thus
masking the effect of glucose. None of the different glucose
concentrations at the different exposure times caused a
statistically significant difference (𝑃 > 0.05) in both wt and
Egr-1−/− cMSCs (Figure 2). Interestingly, cMSCs survived
in absence of glucose up to 7 days as shown in Figure 2.
As control, growth at basal conditions (25mM glucose and
10% FBS) of Egr-1−/− cMSCs was significantly enhanced
compared towt cMSCsup to 48 hours (Supplementary Figure
2, available online at http://dx.doi.org/10.1155/2014/254793).
Nevertheless, the decrease in cell growth at basal conditions
in wt cMSCs cannot be imputable to an increase in cell
apoptosis as shown in Supplementary Figure 2.1, where
the percentage of Annexin-V+ cMSCs (early apoptosis) is
comparable in wt and Egr-1−/− mice at both 24 and 48 hours
(𝑃 = 0.33 at 24 hours; 𝑃 = 0.37 at 48 hours). In addition,
propidium iodide counterstaining, used to exclude late
apoptosis and necrotic cells, shows no statistically significant
difference between cMSCs derived from wt and Egr-1−/−
mice (𝑃 = 0.24 at 24 hours and 𝑃 = 0.76 at 48 hours).
3.2. Colony Forming Ability after Glucose Administration. We
investigated whether glucose variations could influence the
clonogenic capacity of cMSCs in presence or absence of the
Egr-1 gene. Under low serum concentration, only cMSCs
derived from Egr-1−/− were able to generate clones (data
not shown). This suggests that wt cMSCs require a higher
concentration of serum for their clonogenic ability. In fact,
increased concentrations of glucose in culture significantly
decrease the number of colonies formed by wt cMSCs
compared to the absence of glucose (25mM and 50mM all
𝑃 < 0.01, Figure 3). Glucose variations did not affect the
ability of forming colonies in Egr-1−/− cMSCs (all 𝑃 > 0.05).
3.3. Transcriptional Activity of Egr-1−/− and Egr-1−/− Target
Genes. We next aimed to evaluate whether in cMSCs derived
from wt and Egr-1−/− mice the glycolytic stimuli could be
reflected into variations of Egr-1 mRNA levels and its tran-
scriptional coactivatorwith histone acetyl transferase activity,
p300 [11, 29, 30]. We also investigated the canonical GLUT-
1 and the cardiac specific GLUT-4 [31] glucose transporters
and the specific glucose and Egr-1 responsive growth factor
genes VEGF and TGF𝛽-1.
To this purpose, cells were administered with different
concentrations of glucose (no glucose, 25, and 50mM) for
2 hours and the gene expression profile was analyzed by
RT-PCR. The 25mM dose culture condition, which is the
standard concentration of glucose employed for basal growth
of cMSCs in our culture conditions, was set as the reference
dose for normalization of results.
A striking upregulation of Egr-1 transcription (𝑃 < 0.01)
was induced in absence of glucose, which was significantly
higher than that obtained after 2 hours of 50mM condition-
ing in wt cMSCs (Figure 4(a)). Egr-1 mRNA level was absent
in Egr-1−/− cMSCs in all conditions, as expected.
Similarly (Figure 4(b)), a significant upregulation of p300
(𝑃 < 0.01), GLUT-1 (𝑃 < 0.01), and GLUT-4 (𝑃 < 0.01)
transcriptional levels was observed in wt cMSCs in absence
of glucose and to a lesser extent after 50mM of glucose (all
𝑃 < 0.01).
6 BioMed Research International
80
60
40
20
0
N
um
be
r o
f c
ol
on
ie
s/
80
0
ce
lls
∗ ∗
∗ ∗
Wt
25mM 50mMNo glucose
(a)
150
100
50
0
N
um
be
r o
f c
ol
on
ie
s/
80
0
ce
lls
25mM 50mMNo glucose
Egr-1−/−
(b)
Figure 3: The number of clones significantly decreases in wt cMSCs at increased concentrations of glucose. Differently, glucose variations
does not influence the clonogenic capacity of cMSCs in Egr-1−/− cMSCs. ∗∗𝑃 < 0.01.
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Figure 4: Gene expression profile of cMSCs after in vitro glucose conditioning. (a) Egr-1 mRNA levels in wt cMSCs are significantly increased
in absence of glucose and compared to the 50mM condition. A similar fashion can be observed as well with regard to (b) p300, (c) GLUT-1,
and (d) GLUT-4. Differently, the same mRNA gene levels are significantly downregulated or unaffected in Egr-1−/− cMSCs compared to the
basal condition. The 25mM condition was considered as reference. ∗𝑃 < 0.05. ∗∗𝑃 < 0.01.
Interestingly, statistically significant variations of p300,
GLUT-1, and GLUT-4 mRNA levels were observed also in
Egr-1−/− cMSCs in absence of glucose (𝑃 < 0.01) com-
pared to the basal level, but not after the 50mM glucose
dosage.
In addition (Figure 5(a)), glucose deprivation of wt
cMSCs strongly upregulated the TGF𝛽-1 mRNA levels (𝑃 <
0.001), which significantly decreased at the glucose concen-
trations of 50mM (𝑃 < 0.001). Conversely, a significant
decrease in TGF𝛽-1 mRNA levels was detected in absence
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Figure 5: (a) The absence of glucose in wt cMSCs is able to induce a striking upregulation of TGF𝛽-1, whose mRNA levels significantly
decrease at 50mM glucose. In Egr-1−/− cMSCsmRNA levels are significantly downregulated compared to the basal condition both in absence
and at 50mM of glucose. (b) VEGF mRNA levels are significantly increased at the highest concentration of glucose in wt cMSCs, which is
also statistically significantly increased compared to the absence of glucose, whereas in absence of Egr-1 gene this fluctuation is abolished.
The 25mM condition was considered as reference. ∗𝑃 < 0.05. #𝑃 < 0.0001.
N
o 
gl
uc
os
e
Acetylated H3
H3 total
25
m
M
5
0
m
M
N
o 
gl
uc
os
e
25
m
M
5
0
m
M
Wt Egr-1−/−
(a)
#
#
Fo
ld
 H
3
ac
et
yl
at
io
n
N
o 
gl
uc
os
e
25
m
M
5
0
m
M
N
o 
gl
uc
os
e
25
m
M
5
0
m
M
2.0
2.5
1.0
0.6
0.4
0.2
0.0
Wt
Egr-1−/−
(b)
Figure 6: (a) Western Blot representative images of acetylated and total H3 histone in cMSCs derived from wt and Egr-1−/− mice when
subjected to glucose variations in culture. (b) The densitometry analysis shows that in absence of glucose acetylated protein levels of H3
histone significantly increase in wt but not in Egr-1−/− cMSCs. At increased concentrations of glucose acetylated protein levels of H3 histone
significantly decrease compared to the absence of glucose in wt cMSCs, whereas they fairly increased in Egr-1−/− cMSCs. #𝑃 < 0.0001.
(𝑃 < 0.001) and at 50mM of glucose (𝑃 < 0.001) in Egr-1−/−
cMSCs.
However, in wt cMSCs the conditioning with 50mM
of glucose but not its absence induced upregulation of
VEGF mRNA levels (𝑃 < 0.05). In Egr-1−/− cMSCs,
the VEGF mRNA levels were not significantly deregulated
(Figure 5(b)).
3.4. Epigenetic Modifications. Finally, given that glucose has
been demonstrated to induce epigenetic modifications [11]
and that p300, the Egr-1 transcriptional coactivator with
histone acetyl transferase activity, is downregulated in Egr-
1−/− cMSCs, we have asked whether this could be the result of
epigenetic changes.
We show in Figures 6(a) and 6(b) that the protein levels
of acetylated H3 histone in wt cMSCs at basal conditions
(25mM) were similar to those of Egr-1−/− cMSCs. Interest-
ingly, in the absence of glucose, the protein levels of acetylated
H3 histone were strongly increased in wt but not in Egr-1−/−
cMSCs.
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The acetylated protein levels of H3 histone were signif-
icantly decreased in wt cMSCs in presence of high concen-
trations of glucose (𝑃 < 0.001 25mM and 𝑃 < 0.001 50mM
both versus no glucose). whereas only amoderate but not sta-
tistically significant increase of the levels could be appreciated
in Egr-1−/− cMSCs. In summary, deprivation of glucose in wt
cMSCs could be a strong stimulus to induce pan-acetylation
of H3 histone compared to high glucose concentrations. Egr-
1−/− cMSCs apparently are unable to induce pan-acetylation
of H3 histone under a stress condition such as the glucose
deprivation. However, further experiments are required to
confirm our observations.
4. Discussion
Hyperglycemia represents the hallmark sign of diabetes, and
it is also an independent risk factor for short- and long-term
mortality in acutemyocardial infarction. In spite of the recent
advances in using MSCs as regenerative therapy for treating
cardiac diseases and diabetes, studies providing an exhaustive
model based on the “glucose-MSCs-heart triad” are still
lacking [21]. Specifically, the improvement of MSC-based
therapies for cardiac diseases with diabetes complications
must firstly embrace a deeper knowledge on the impact of
glucose on MSCs, even prior to their clinical administra-
tion. To date, this issue is only partially explored. In fact,
understanding the effects of glucose on MSCs does not only
represent a main objective to clarify the pathophysiology of
hyperglycemia. But, more importantly, it may provide better
understanding to enable therapeutic targeting of the impact
that glucose has on both the metabolism and the therapeutic
potential of the MSC pool.
Physiologically, the cardiac cell metabolism is based on
the catabolism of fatty acids, in order to satisfy the contractile
function [32]. However, after a myocardial infarction, this
scenario is completely overturned. In fact, the myocardium
shifts from the basal fatty acid to the glucose metabolism, in
order to gain the energy to escape the damage [33, 34]. This
adaptive response should include also resident cMSCs.
The effects of glucose on MSCs are still far from being
clarified. High glucose has been reported to enhance the
proliferation of embryonic stem cells [35] but to decrease that
of in rat MSCs [5]. Glucose has no effect on proliferation of
human bonemarrow-derivedMSC, either at short [8] or long
exposure durations [3].
More interestingly, high glucose seems not even to be an
obstacle for the improvement of MSC-based therapies [36],
in spite of the fact that a persistent exposure to elevated levels
of glucose can be responsible of the detrimental effects caused
by hyperglycemia such as the increased levels of reactive oxy-
gen species and the production of advance glycated end prod-
ucts known as AGEs [37–40]. We confirm that in a murine
system cMSC proliferation in low serum is not affected by
changing the glucose levels in themedium and show that Egr-
1 does not seem to be involved in the proliferative response to
glucose. The biological explanation of these observations has
likely to be found in a potential “basal glucose tolerance” of
this stem cell type. Since glucose tolerance is not mediated by
Egr-1, different mechanisms should be involved such as the
JAK/STAT or the p38 MAP signaling pathways as described
[8].
It is surprising that cMSCs survive even in absence of
glucose. Indeed, adipose tissue-derived MSCs have been
reported to survive using low ATP levels in presence of
severe hypoxia [41].This is an important biological advantage
for MSCs that can be functional in challenging unexpected
periods of stress and this in turn would prolong their life in
the uncommitted state.
Referring to the impact of glucose on MSC clonogenic
ability, it has been shown that high glucose concentration
can alter the regenerative potential of MSCs [6] as for the
circulating angiogenic cells [42]. We show that increased
concentrations of glucose decrease the number of clones
generated by wt but not by Egr-1−/− cMSCs, where the role
of Egr-1 gene as biological glucose sensor is not preserved.
Given that the combination of low serum and glucose
represents a severe metabolic stress for the clonogenic ability,
is the lack of Erg-1 functional to preserve the self-renewal
properties of MSCs?
In other tissues such as the hematopoietic stem cell (HSC)
compartment, Egr-1 is known to be an inhibitor of self-
renewal, playing also a crucial role in maintaining HSCs in a
quiescent statewithin the bonemarrow [43]. As consequence,
Egr-1−/− mice have an increased number of HSCs in the bone
marrow [43, 44]. This scenario combined with the glucose
context makes possible that the wt cMSC pool protects itself
from unnecessary concentrations of glucose by decreasing its
clonogenic rate, and thus avoiding the risk of stem cell pool
depletion. Egr-1 could participate in this response, acting as
both biological glucose sensor and as inhibitor of the self-
renewal capacity.
A minimal concentration of glucose must be maintained
in vitro to guarantee cell survival and viability. Our results
show that glucose deprivation is a stronger stimulus to
induce Egr-1 upregulation in wt cMSCs compared to other
concentrations of glucose. In addition, the widely expressed
GLUT-1 and the cardiac specific GLUT-4 glucose trans-
porters mRNA levels are both greatly affected by glucose
deprivation, also p300 expression, which has been reported
to directly influence both the activity and the function of Egr-
1 [45], is affected by glucose deprivation. It is interesting to
observe that the phenotype changes of cMSCs in response to
glucose variations is completely abolished in Egr-1−/− cases.
To the best of our knowledge, glucose deprivation linked
to Egr-1, as reproduced in vitro by growing wt and Egr-1−/−
cMSCs in cell culture media depleted of glucose, has been
not sufficiently examined. Some reports have shown that
the deprivation of glucose is able to attenuate neurosphere
formation efficiency but no neuronal maturation by human
periodontal ligament-derived MSCs [46] and that glucose
deprivation-induced necrosis, a distinct hallmark of the
metabolic stress present in solid tumors in combination with
hypoxia, is specifically regulated by Egr-1 [47]. Moreover, if
MSCs are conditioned with glucose depletion, they become
even able to enhance their regenerative properties after
myocardial infarction [7]. All together our results would
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indicate that Egr-1 by acting as an early stress response gene
functions as a decoder to activate specific responses when
glucose is the only substrate available.
Hyperglycemia is known to inhibit the VEGF-VEGF
receptor 2 signaling axis, contributing to endothelial dys-
function [48] and causing impairment of the neoangiogenic
response in presence of a cardiovascular insult [49]. Our
results show that VEGF mRNA levels are upregulated in wt
cMSCs conditioned with high glucose concentrations.
This discrepancy could be explained by considering that
glucose metabolism is strictly cell type- and tissue dependent
and that the glucose mediated effects such as those observed
in endothelial progenitor cells [49] may be not reproducible
or are differently modulated in other stem cell pools such as
MSCs. Specific reports on MSCs indicate that the amount of
VEGF released in culture is unmodified by different levels
of glucose [8]. More interestingly, the VEGF mRNA levels
are not modulated in Egr-1−/− cMSCs. A direct influence
of Egr-1 on VEFG has been recently demonstrated in lung
cancer cells, either by binding to the proximal region of the
VEGF promoter and activating the VEGF expression or by
enhancing the hypoxia inducible factor 1alpha- (HIF-1alpha-)
mediated VEGF expression [50].
Exposure to high glucose normally increases all three
TGF-𝛽 isoforms in renal cortical fibroblasts [51] as well as in
human bone marrow-derived MSCs, thus regulating several
cellular processes including proliferation [52]. However, the
final effect is cell type dependent. Therefore, TGF-𝛽1 can act
as inhibitor of cell proliferation in most epithelial cells or as a
stimulator ofMSC proliferation and expansion [53]. Our data
show that increasing the concentration of glucose induces the
downregulation of TGF-𝛽1 mRNA levels in wt cMSCs. Egr-1
represents a key regulator of TGF𝛽-1, which in turn positively
regulates the expression of p300 [29]. This would explain
why the fluctuation of TGF𝛽-1 mRNA levels is suppressed in
Egr-1−/− cMSCs and p300 as well.
Several environmental stimuli, including glucose, can
ultimately cause epigenetic modifications, which determine
gene activation or repression by altering DNA accessibility
to transcription factors [11, 54]. In particular, the acetylation
state is expression of potential active transcriptional sites.
MSCs are not excluded from this process. In adipose tissue-
derived MSCs, low levels of acetylated histone H3 and high
levels of trimethyl lysine 27 in H3 have been associated
with Nkx2.5 and GATA-4 promoters, highlighting a role
for the epigenetic modulations in regulating preferential cell
lineage commitments [54]. DNA methylation and histone
acetylation have been also involved in the control of cartilage
differentiation of MSCs [55]. In addition, although in other
cell systems such as the vascular endothelial cells, epigenetic
modifications have been shown to be caused by transient
hyperglycemia, thus providing a plausible explanation for the
long lasting effects of diabetes [11]. Specifically, modification
of 4 and 9 lysine of the H3 histone tail has recently been
linked to the changes in gene expression brought up by
hyperglycemia [56].
Egr-1 is known to be involved in epigenetic modifications
[57, 58]. However, so far, there are no studies investigating
whether glucose variations can induce Egr-1-associated epi-
genetic changes in cMSCs.
Our data firstly are the first evidence that such epigenetic
modifications in cMSCs can occur under glycolytic stimuli
and not only in response to hyperglycemia. This observation
could be explained by the ability of MSCs, including cMSCs,
to modify their phenotype/genotype according to the envi-
ronmental stimuli and would suggest that Egr-1−/− cMSCs
are potentially less “prone” to actively respond to glucose
variations.
The histone acetylation is a less stable epigenetic modi-
fication than methylation [59]. With the fact that our data
are the result of 2 hours of exposure to glucose variations,
it can be excluded that they are associated with a “metabolic
memory” induced by glucose.
It is clear that the acetylation of H3 histone is not com-
pletely abolished inEgr-1−/−mice, and that othermechanisms
are involved in the DNA remodeling. However, the downreg-
ulation of p300 mRNA levels (a transcriptional coactivator
with histone acetyl transferase activity, which has been shown
to modify lysine residues on H3 and H4 [11]), together with
the low protein levels of acetylated H3 histone found in
Egr-1−/− cMSCs, seems to suggest that themechanism under-
lying the response to glucose variations in MSCs in relation
to Egr-1 is p300 dependent, at least indirectly. We cannot
rule out that other partners are involved in such process.
For instance, the complex ATF5/p300 has been recently
considered important for Egr-1 activation, cell proliferation,
and survival [30].
5. Conclusions
In conclusion, our data suggest that Egr-1 could play a
role as biological glucose sensor in cMSCs in response to
glucose variations. Epigenetic changes could represent a key
mechanism to determine the glucose-induced response of
Egr-1. However, future studies are needed to determine if and
which metabolic processes Egr-1 associated are affected in
cMSCs.
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